A Study of Single and Multiple Doses of HRS-6257 in Healthy Subjects

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Pain

In brief

This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of HRS-6257 in healthy volunteers.

Key facts

Study ID
NCT07301333
Run by
Shanghai Hengrui Pharmaceutical Co., Ltd.
People needed
80
Starts
2025-12-30
Expected to finish
2026-05-01
Last updated by the study team
2026-04-07

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.